Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
35,595
result(s) for
"Aging General"
Sort by:
Aging in world history
\"Contemporary concerns about aging societies have stimulated interest in past ways of growing old, and whilst historians have investigated the experience of the aged, cultural representations of old age, and the phenomenon of demographic ageing, however the literature has been overwhelmingly western. This study reviews the world-wide literature on aging and seeks to move beyond received wisdom about attitudes and experiences running from the ancient world to the present.Aging in World History will introduce students and general readers to historical ways of thinking about aging in two senses: the experience of individuals and the transformation of populations. The first section introduces theoretical concerns, understandings of \"natural\" or \"traditional\" ways of growing old, and diverse cultural prescriptions and representations. The second section covers key issues from the medieval to the early modern era. The third section looks at transitions to modernity, whilst the final part explores the contemporary world, before concluding with an overview of past, present and future\"-- Provided by publisher.
Book
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
Respiratory syncytial virus causes clinically significant illness in children and adults. In a placebo-controlled trial, a prefusion stabilized F protein vaccine led to an 83% lower risk of RSV infection.
Journal Article
Cardiovascular Safety of Testosterone-Replacement Therapy
In a randomized trial involving men with hypogonadism and preexisting or a risk of cardiovascular disease, testosterone therapy was noninferior to placebo with respect to major adverse cardiac events.
Journal Article
Understanding well-being in the oldest old
\"The demographic and social structure of most industrialized and developing countries are changing rapidly as infant mortality is reduced and population life span has increased in dramatic ways. In particular, the oldest-old (85+) population has grown and will continue to grow. This segment of the population tends to suffer physical and cognitive decline, and little information is available to describe how their positive and negative distal experiences, habits, and intervening proximal environmental influences impact their well-being, and how social and health policies can help meet the unique challenges they face. Understanding Well-Being in the Oldest Old is the outcome of a four-day workshop attended by U.S. and Israeli scientists and funded by the U.S.-Israel Bi-National Science Foundation to examine both novel and traditional paradigms that could extend our knowledge and understanding of the well-being of the oldest old. This volume engages social scientists in sharing methods of understanding, and thereby possibly improving, the quality of life of older populations, especially among the oldest old\"-- Provided by publisher.
Book
Trial of Solanezumab in Preclinical Alzheimer’s Disease
Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer's disease have had mixed results.
We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer's disease. Persons 65 to 85 years of age with a global Clinical Dementia Rating score of 0 (range, 0 to 3, with 0 indicating no cognitive impairment and 3 severe dementia), a score on the Mini-Mental State Examination of 25 or more (range, 0 to 30, with lower scores indicating poorer cognition), and elevated brain amyloid levels on
F-florbetapir positron-emission tomography (PET) were enrolled. Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 mg intravenously every 4 weeks or placebo. The primary end point was the change in the Preclinical Alzheimer Cognitive Composite (PACC) score (calculated as the sum of four z scores, with higher scores indicating better cognitive performance) over a period of 240 weeks.
A total of 1169 persons underwent randomization: 578 were assigned to the solanezumab group and 591 to the placebo group. The mean age of the participants was 72 years, approximately 60% were women, and 75% had a family history of dementia. At 240 weeks, the mean change in PACC score was -1.43 in the solanezumab group and -1.13 in the placebo group (difference, -0.30; 95% confidence interval, -0.82 to 0.22; P = 0.26). Amyloid levels on brain PET increased by a mean of 11.6 centiloids in the solanezumab group and 19.3 centiloids in the placebo group. Amyloid-related imaging abnormalities (ARIA) with edema occurred in less than 1% of the participants in each group. ARIA with microhemorrhage or hemosiderosis occurred in 29.2% of the participants in the solanezumab group and 32.8% of those in the placebo group.
Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer's disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.).
Journal Article
Youth cultures, transitions, and generations : bridging the gap in youth research
\"Within the diversity of contemporary youth research there are two dominant streams that can be categorized under the broad headings of 'transitions' and 'cultures' perspectives. This collection sets forth a challenge to youth studies, with the contributors arguing that social change means it is no longer possible to understand the experience of young people through this transitions/cultures prism. The future of youth studies, it is argued, will require new conceptual foundations, capable of bridging the gap between transitions and cultures approaches to researching youth. The chapters, including contributions from some of the most established names in contemporary youth studies, draw on a wide variety of alternative concepts, including generation, assemblage, field and belonging to rethink how the study of young lives should be pursued in the coming decades. \"-- Provided by publisher.
Book
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.
Journal Article
Embracing age : how Catholic Nuns became models of aging well
\"Embracing Age: How Catholic Nuns Became Models of Aging Well examines a community of individuals whose aging trajectories contrast mainstream American experiences. In mainstream American society, aging is presented as a \"problem,\" a state to be avoided as long as possible, a state that threatens one's ability to maintain independence, autonomy, control over one's surroundings. Aging \"well\" (or avoiding aging) has become a 21st century American preoccupation. Embracing Age provides a window into the everyday lives of American Catholic nuns who experience longevity and remarkable health and well-being at the end of life. Catholic nuns aren't only healthier in older age, they are healthier because they practice a culture of acceptance and grace around aging. Embracing Age demonstrates how aging in the convent becomes understood by the nuns to be a natural part of the life course, not one to be feared or avoided. Anna I. Corwin shows readers how Catholic nuns create a cultural community that provides a model for how to grow old, decline, and die that is both embedded in American culture and quite distinct from other American models\"-- Provided by publisher.
BOOK
Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma
In patients with subdural hematoma and an indication for surgical evacuation, middle meningeal artery embolization plus surgery led to a lower risk of reoperation for recurrence or progression within 90 days than surgery alone.
Journal Article